mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease

INTRODUCTION: In men with metastatic castration-resistant prostate cancer (mCRPC) scheduled for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), biochemical response is assessed based on repeated measurements of prostate-specific antigen (PSA) levels. We aimed to determi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartrampf, Philipp E., Bundschuh, Ralph A., Weinzierl, Franz-Xaver, Serfling, Sebastian E., Kosmala, Aleksander, Seitz, Anna Katharina, Kübler, Hubert, Buck, Andreas K., Essler, Markus, Werner, Rudolf A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606086/
https://www.ncbi.nlm.nih.gov/pubmed/35852555
http://dx.doi.org/10.1007/s00259-022-05910-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606086/
https://www.ncbi.nlm.nih.gov/pubmed/35852555
http://dx.doi.org/10.1007/s00259-022-05910-w

Ejemplares similares